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Abstract
Aims/hypothesis The aim of this work was to evaluate geographical variability and trends in the prevalence of diabetic
ketoacidosis (DKA), between 2006 and 2016, at the diagnosis of childhood-onset type 1 diabetes in 13 countries over three
continents.
Methods An international retrospective study on DKA at diagnosis of diabetes was conducted. Data on age, sex, date of diabetes
diagnosis, ethnic minority status and presence of DKA at diabetes onset were obtained from Australia, Austria, Czechia,
Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA and the UK (Wales). Mean prevalence
was estimated for the entire period, both overall and by country, adjusted for sex and age group. Temporal trends in annual
prevalence of DKA were estimated using logistic regression analysis for each country, before and after adjustment for sex, age
group and ethnic minority status.
Results During the study period, new-onset type 1 diabetes was diagnosed in 59,000 children (median age [interquartile range],
9.0 years [5.5–11.7]; male sex, 52.9%). The overall adjusted DKA prevalence was 29.9%, with the lowest prevalence in Sweden
and Denmark and the highest in Luxembourg and Italy. The adjusted DKA prevalence significantly increased over time in
Australia, Germany and the USA while it decreased in Italy. Preschool children, adolescents and children from ethnic minority
groups were at highest risk of DKA at diabetes diagnosis in most countries. A significantly higher risk was also found for females
in Denmark, Germany and Slovenia.
Conclusions/interpretation DKA prevalence at type 1 diabetes diagnosis varied considerably across countries, albeit it was
generally high and showed a slight increase between 2006 and 2016. Increased awareness of symptoms to prevent delay in
diagnosis is warranted, especially in preschool children, adolescents and children from ethnic minority groups.
Keywords Children with diabetes . Complications . Diabetic ketoacidosis . Diagnosis of diabetes . Epidemiology . Type 1
diabetes
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Introduction
Clinical presentation of type 1 diabetes is often associated
with diabetic ketoacidosis (DKA), which may lead to
increased morbidity and mortality risk and healthcare expen-
diture [1]. DKA at diabetes diagnosis may arise from delayed
diagnosis due to lack of awareness of diabetes symptoms or
failure of a healthcare provider to consider diabetes when a
child presents with abdominal pain, nausea and vomiting [2].
It is associated with both long-term poor glycaemic control
and subsequent recurrent episodes of DKA [3–6]. DKA at
diabetes diagnosis is also associated with long-term spatial
memory performance and is associated with lower cognitive
scores and altered brain growth [7, 8].
Screening of genetic risk and beta cell autoantibodies
in high-risk individuals allows an early diagnosis of type
1 diabetes [9–12] and, consequently, possible prevention
of DKA at diabetes diagnosis. However, a cost–benefit
analysis of a screening programme in the general popu-
lation showed that costs far outweighed the economic
benefits [13]. The impact of individual knowledge and
community-based information and education campaigns
in reducing DKA at type 1 diabetes onset has been
disappointing [14–16]. These studies have suggested that
knowledge of the symptoms of diabetes does not neces-
sarily appear to translate to an earlier diagnosis. It is
worthwhile noting that even, in the T1D Exchange
registry [17], a relatively high percentage of children
who had a parent with type 1 diabetes (and, hence,
knowledge of the classic symptoms of diabetes) present-
ed with DKA (24%). Community education programmes,
in which DKA was reduced when compared with a no-
intervention group, were intensive and also specifically
targeted primary care physicians, teachers and early
childhood workers, using face-to-face education and
written action plans [18, 19]. On the other hand, other
studies identified clinical and sociodemographic factors
associated with the presence of DKA at diabetes onset
[20, 21], suggesting specific targets for intervention to
raise awareness of the disease.
Reported prevalence estimates of DKA at diabetes diagno-
sis vary between countries and there is some evidence that
prevalence is associated with a country’s socioeconomic
factors [22]. However, the definitions of DKA, reporting of
venous pH in medical records, inclusion criteria, age ranges of
individuals included and statistical analyses differ consider-
ably between studies [22].
Despite improvements in medical care over the years, and
in diabetes care after diabetes onset, the burden of DKA at
diagnosis remains high in many countries [14, 23–25]. DKA
in individuals with known diabetes has been compared in an
international setting, but DKA prevalence at diagnosis of type
1 diabetes has not [26]. Therefore, the aim of this study was to
evaluate worldwide geographical variability and time trends
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in the prevalence of DKA at diagnosis of childhood-onset type
1 diabetes during 2006–2016, in developed healthcare
systems, according to country, sex, age and ethnic minority
status.
Methods
Study population An international collaboration proposed a
retrospective, population-based study on DKA at type 1 diabe-
tes diagnosis during 2006–2016, in children aged 6 months to
14.9 years. This upper age limit was chosen since most regis-
tries for type 1 diabetes include children under 15 years of age.
Children under 6 months of age were not included to exclude
cases of neonatal diabetes. Requirements for participating coun-
tries included nationwide or regional availability of data for at
least 6 consecutive years in the study period, and willingness to
share anonymised patient-level data for joint analysis.
DKA was defined according to the International Society
for Pediatric and Adolescent Diabetes (ISPAD) criteria
(venous pH <7.3 or serum bicarbonate <15 mmol/l) or docu-
mented information on DKA (yes/no) according to the physi-
cian providing medical care at diagnosis.
Data collection Required data per individual included were
age, date of diabetes diagnosis, sex, ethnic minority status (if
available), and venous pH, serum bicarbonate, or information
on DKA (yes/no).
Thirteen countries participated in the project (Fig. 1): ten
countries from Europe (Austria, Germany and Luxembourg
[Diabetes Patients Follow-up registry (DPV)], Czechia
[Czech National Childhood Diabetes Register (ČENDA)],
Denmark [Danish Registry of Childhood and Adolescent
Diabetes (DanDiabKids)], Italy [Study Group for diabetes of
the Italian Society for Paediatric Endocrinology and
Diabetes], Norway [Norwegian Childhood Diabetes Registry
(NCDR)], Slovenia [Slovenian national diabetes type 1 regis-
try], Sweden [The Swedish Paediatric Diabetes Quality
Registry, SWEDIABKIDS] and the UK [Wales; The Brecon
Group Register and Brecon Cohort (Welsh Paediatric
Diabetes Interest Group)]); two regions from Australasia
(Auckland, New Zealand and Australia [Australasian
Diabetes Data Network (ADDN)]); and a consortium of sites
from the USA (SEARCH for Diabetes in Youth-US).
The European participating centres defined ethnic minority
status as at least one parent born outside the country with a
positive migration history, or using a list of ethnic categories
(African, Asian, mixed). The USA (SEARCH) included in
ethnic minority status all races/ethnicities other than non-
Hispanic white. The New Zealand (Auckland) centre defined
ethnic minority status as Māori, Pacific Islander, Indian,
South-East Asian, African or Middle Eastern ethnicities. The
Australian centres included in ethnic minority status,
Aboriginal and Torres Strait Islander people and immigrants
from a non-Anglo background.
Data sources Data sources consisted of population-based
registries (Australia, New Zealand [Auckland], Austria,
Czechia, Denmark, Germany, Luxembourg, Norway,
Slovenia, Sweden, Wales), nationwide clinical records
(Italy) and a national multicentre study (USA [SEARCH])
with a completeness of coverage of at least 90% during the
study period, as previously described [21, 25, 27–33]. All data
owners gave the permission for publication. Data were collect-
ed from each country and integrated in a joint SAS database.
To evaluate the association of DKA prevalence with gross
domestic product (GDP) per capita and human development
index (HDI), the mean GDP and HDI for the 13 participating
countries were extracted for 2006–2016 from the reports of
the United Nations Development Programme [34]. HDI
measures the development of a country using three dimen-
sions, namely life expectancy at birth, expected years of
schooling and the gross national income per capita. The
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Fig. 1 Map showing 13 centres from three continents (a) the USA, (b)
Europe and (c) Australasia, participating in the DKA international collab-
oration project (whole nations, administrative units or clinic centres are
shown). Maps by https://vemaps.com/, adapted by the authors
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association between DKA prevalence and countries’ latitudes
was also analysed.
Statistical analysis DKA at diagnosis of type 1 diabetes was
evaluated as raw and standardised prevalence and 95% CI.
The prevalence of DKAwas standardised by sex and age over
the whole study population using the direct method. Raw and
standardised prevalences were computed across the entire
period, overall and by country.
Mean prevalence was also calculated according to age
group and sex. Comparisons between sexes in each age group
were performed using the χ2 test. The p values were adjusted
for multiple comparisons using the procedure proposed by
Benjamini and Hochberg [35].
DKA prevalence by country and year at diagnosis of type 1
diabetes, adjusted for sex and age groups, was estimated using
multiple log–binomial regression analysis.
Unadjusted temporal trends in DKA prevalence were esti-
mated using log–binomial regression analysis by country. Next,
to explore whether changes in demographics of type 1 diabetes
explain the observed trends, we performed multiple log–
binomial regression analysis to estimate temporal trends adjust-
ed for sex, age group and ethnic minority status, obtaining
prevalence ratios for annual changes across countries.
The association between prevalence of DKA at diagnosis
of diabetes and GDP per capita, HDI and countries’ latitude
was evaluated by Spearman correlation coefficients, weighted
by the number of cases of type 1 diabetes in each country and
95%CI.
All the statistical analyses were performed using the SAS
System vs 9.4 (SAS Institute, Cary, NC, USA). A p value
<0.05 was defined as statistically significant.
Results
DKA prevalence at type 1 diabetes diagnosis During the
11 year period, in our cohort, there were 59,000 new diagnoses
of type 1 diabetes (median age 9.0 years, interquartile range
5.5–11.7 years). Characteristics of participants are reported in
electronic supplementary material (ESM) Table 1; 52.9% were
male and a total of 17,205 (29.2%; 95% CI 28.82, 29.56) chil-
dren were considered to have had DKA at onset of type 1
diabetes. Table 1 shows the number of children with newly
diagnosed type 1 diabetes and raw and standardised DKA prev-
alence (95% CI). The overall mean prevalence of DKA at diag-
nosis was 29.9%, with six countries (Australia, Denmark,
Germany, Norway, Sweden, Wales) reporting significantly
lower prevalence of DKA and five countries (Austria, Italy,
Luxembourg, Slovenia, USA) significantly higher prevalences.
The lowest prevalence was found in Sweden, whereas the
Table 1 Cases of type 1 diabetes,
DKA prevalence and
standardised DKA prevalence, at
type 1 diabetes diagnosis across
the study population between
2006 and 2016
Country New diagnosis
of type 1 diabetes (n)
DKA prevalence,
% (95% CI)
Standardised DKA
prevalence, % (95% CI)a
Australia (ADDN) 4428 24.9 (23.6, 26.2) 24.9 (23.4, 26.4)
Austria 1504 38.0 (35.6, 40.5) 37.7 (34.6, 40.7)
Czechia 2261 28.8 (27.0, 30.7) 28.6 (26.4, 30.8)
Denmark 3084 20.7 (19.3, 22.1) 20.8 (19.1, 22.4)
Germany 19,127 26.8 (26.2, 27.4) 26.8 (26.1, 27.5)
Italy 10,317 41.2 (40.3, 42.2) 41.2 (39.9, 42.4)
Luxembourg 192 43.8 (36.9, 50.9) 43.8 (34.5, 53.2)
New Zealand (Auckland) 670 26.3 (23.1, 29.7) 26.3 (22.4, 30.2)
Norway 3331 22.1 (20.7, 23.5) 22.1 (20.5, 23.7)
Slovenia 471 40.3 (36.0, 44.8) 39.9 (34.2, 45.6)
Sweden 6457 19.5 (18.6, 20.5) 19.5 (18.4, 20.6)
USA (SEARCH) 5485 36.9 (35.6, 38.1) 37.0 (35.4, 38.6)
UK (Wales) 1673 25.0 (23.0, 27.2) 25.0 (22.6, 27.4)
All countries combined 59,000 29.2 (28.8, 29.6)
a Standardised on whole study population
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Fig. 2 Mean DKA prevalence (per 100 people) and 95% CI at type 1
diabetes diagnosis according to year of age (all countries combined)
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Table 2 Mean DKA prevalence (per 100 people) at type 1 diabetes diagnosis across the study population, according to sex and age group
Country Female sex Male sex p valuea
Type 1 diabetes (n) DKA prevalence (95% CI) Type 1 diabetes (n) DKA prevalence (95% CI)
0.5–4.9 years
Australia (ADDN) 483 31.3 (26.3, 36.2) 561 32.6 (27.9, 37.3) 0.874
Austria 164 45.7 (35.4, 56.1) 220 45.0 (36.2, 53.8) 0.935
Czechia 275 34.5 (27.6, 41.5) 316 34.5 (28.0, 41.0) 0.989
Denmark 241 24.5 (18.2, 30.7) 287 17.4 (12.6, 22.2) 0.153
Germany 1948 33.0 (30.5, 35.6) 2047 31.0 (28.6, 33.4) 0.450
Italy 1115 51.0 (46.8, 55.2) 1222 50.2 (46.2, 54.1) 0.874
Luxembourg 13 76.9 (46.2, 95.5) 24 54.2 (24.8, 83.5) 0.450
New Zealand (Auckland) 56 28.6 (14.6, 42.6) 63 22.2 (10.6, 33.8) 0.694
Norway 288 24.3 (18.6, 30.0) 345 26.7 (21.2, 32.1) 0.747
Slovenia 60 53.3 (34.9, 71.8) 71 35.2 (21.4, 49.0) 0.145
Sweden 669 19.7 (16.4, 23.1) 755 17.2 (14.3, 20.2) 0.481
USA (SEARCH) 472 41.5 (35.7, 47.3) 568 45.6 (40.1, 51.1) 0.457
UK (Wales) 147 27.9 (19.4, 36.4) 169 38.5 (29.1, 47.8) 0.153
All countries combined 5931 35.2 (33.7, 36.7) 6648 34.4 (33.0, 35.8) 0.326
5–9.9 years
Australia (ADDN) 931 24.0 (20.8, 27.1) 888 18.9 (16.1, 21.8) 0.058
Austria 247 30.8 (23.9, 37.7) 275 32.0 (25.3, 38.7) 0.874
Czechia 433 25.9 (21.1, 30.7) 453 25.4 (20.8, 30.0) 0.935
Denmark 550 20.9 (17.1, 24.7) 537 15.6 (12.3, 19.0) 0.107
Germany 3528 25.4 (23.7, 27.0) 3570 21.8 (20.3, 23.4) 0.019
Italy 1937 37.2 (34.5, 39.9) 2009 35.6 (33.0, 38.2) 0.561
Luxembourg 33 54.5 (29.4, 79.7) 35 31.4 (12.9, 50.0) 0.162
New Zealand (Auckland) 119 22.7 (14.1, 31.2) 111 18.9 (10.8, 27.0) 0.747
Norway 591 21.5 (17.8, 25.2) 620 14.8 (11.8, 17.9) 0.030
Slovenia 82 48.8 (33.7, 63.9) 91 25.3 (15.0, 35.6) 0.026
Sweden 1154 14.9 (12.7, 17.1) 1178 13.8 (11.6, 15.9) 0.694
USA (SEARCH) 1056 37.2 (33.5, 40.9) 985 32.2 (28.6, 35.7) 0.083
UK (Wales) 318 17.3 (12.7, 21.9) 262 26.7 (20.5, 33.0) 0.047
All countries combined 10,979 27.1 (26.1, 28.1) 11,014 24 (23.1, 24.9) <0.001
10–14.9 years
Australia (ADDN) 753 22.8 (19.4, 26.3) 812 25.1 (21.7, 28.6) 0.561
Austria 255 44.7 (36.5, 52.9) 343 35.0 (28.7, 41.2) 0.083
Czechia 347 27.4 (21.9, 32.9) 437 28.6 (23.6, 33.6) 0.874
Denmark 689 22.9 (19.4, 26.5) 780 21.9 (18.6, 25.2) 0.874
Germany 3510 26.5 (24.8, 28.2) 4524 27.5 (26.0, 29.0) 0.561
Italy 1775 41.5 (38.5, 44.5) 2259 39.6 (37.0, 42.2) 0.481
Luxembourg 32 34.4 (14.1, 54.7) 55 38.2 (21.9, 54.5) 0.874
New Zealand (Auckland) 152 32.9 (23.8, 42.0) 169 28.4 (20.4, 36.4) 0.679
Norway 645 23.9 (20.1, 27.6) 842 23.8 (20.5, 27.0) 0.981
Slovenia 82 42.7 (28.6, 56.8) 85 41.2 (27.6, 54.8) 0.935
Sweden 1183 25.0 (22.2, 27.9) 1518 24.3 (21.8, 26.8) 0.874
USA (SEARCH) 1083 32.4 (29.0, 35.8) 1321 38.2 (34.9, 41.6) 0.030
UK (Wales) 363 23.7 (18.7, 28.7) 414 24.6 (19.9, 29.4) 0.874
All countries combined 10,869 29.3 (28.3, 30.3) 13,559 29.8 (28.9, 30.7) 0.444
a p value is adjusted for multiple testing using the Benjamini–Hochberg procedure and it compares DKA prevalence in female sex vs male sex
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highest was observed in Luxembourg. The standardised values
were very close to the raw values in all countries, showing a
small effect of population structure on DKA prevalence.
ESM Table 2 reports prevalence of DKA and the annual
percentage change according to the degree of acidosis for each
country, year and for all countries combined. Both moderate
DKA and severe DKA overall prevalences showed a small but
significant increase over the study period (1.8% and 1.6%,
respectively). A high variability between countries across the
study period was found both for moderate and severe forms of
DKA prevalence. Germany and the USA (SEARCH) reported
increasing annual percentages in moderate DKA and severe
DKA prevalence; Slovenia and Luxembourg reported increas-
ing annual percentages in the moderate and the severe forms,
respectively.
Sex and age differences A significantly higher prevalence of
DKA was found in girls in Denmark and Slovenia, whereas a
higher prevalence was found in boys in Wales (ESM Fig. 1).
Significant differences in mean prevalence of DKA accord-
ing to age group were found for all countries, except Slovenia;
prevalence was higher in children under 5 years of age apart
from in Sweden, Denmark and Auckland (New Zealand)
where the highest proportions were found in adolescents aged
10–14.9 years (ESM Fig. 2). The overall highest mean prev-
alence of DKA (34.8% [95% CI 34.0, 35.6]) was found in
children aged 0.5–4.9 years, whereas higher proportions were
reported in adolescents than in children aged 5–9.9 years
(29.6% [95% CI 29.0, 30.2] vs 25.5% [95% CI 24.9, 26.1],
respectively).
As shown in Fig. 2, the overall highest prevalence was
observed in children under 1 year of age (59.7% [95% CI
53.7, 65.7]), with a decrease in proportions up until 5 years
of age (21.9% [95% CI 20.5, 23.2]) and a slow increase there-
after, as children got older, peaking at around 10–12 years of
age.
Sex differences were also found by age group (Table 2). No
significant differences between boys and girls were found in
the 0.5–4.9 year age group whereas higher prevalences in girls
in the 5–9.9 year age group in Germany, Norway and
Slovenia were reported. A significantly higher prevalence
was found in Wales in boys aged 5–9.9 years and in the
USA in boys aged 10–14.9 years.
Ethnic minority status The overall mean prevalence of DKA
was higher in children of ethnic minority status (36.9% [95%
CI 35.8, 38.0], p< 0.01) than in those of non-minority status
(28.4% [95% CI 28.0, 28.8]) and this observation was
confirmed in most countries, (ESM Fig. 3). No information
on ethnic minority status was collected in Czechia and there
were no children from an ethnic minority background in
Slovenia.
Temporal trend analysis Figure 3 reports the unadjusted annu-
al percentage change in DKA prevalence at type 1 diabetes
diagnosis and ESM Fig. 4 the estimated annual standardised
prevalence of DKA by country. A slight increasing temporal
trend of 0.7% per year over the period of 11 years for all
countries combined was observed. Table 3 shows the results
of multiple log–binomial regression analysis. A significant
increase in prevalence of DKA at diagnosis of diabetes was
found in Australia, Germany and USA, whereas a significant
decrease was observed in Italy during the study period.
Girls were at a significantly higher risk of DKA at diagno-
sis in Denmark, Germany and Slovenia.
A significant negative association between adjusted DKA
prevalence and HDI (r = −0.75 [95% CI −0.90, −0.42]) and
latitude (r = −0.55 [95%CI −0.81, −0.10]) was also observed,
whereas no significant association was found with GDP per
capita (r = −0.47 [95% CI −0.77, 0.01]) (ESM Fig. 5).
Discussion
The major findings of this international joint project were a
high prevalence of children presenting with DKA at diagnosis
and a slight increasing trend in prevalence of DKA at diagno-
sis of type 1 diabetes during 2006–2016 across sites. The
project also highlights large inter-country differences and vari-
ability in the prevalence of DKA at diabetes diagnosis by age
group, sex and ethnic minority status. During the 11 years
studied, a marked increase in DKA at diabetes diagnosis was
clear in the USA (SEARCH) and Australia (ADDN), while in
Germany the increase was small but statistically significant
due to the large number of patients from this country. In
particular, increasing burden of DKA among both youth
[36] and adults [37] was also reported in recent years. The
proportion of children presenting with DKA at diagnosis of
diabetes decreased in Italy over the study years. However,
Italy showed one of the highest prevalences of DKA. The
overall increase in DKA prevalence, although small, is indic-
ative of a general phenomenon that remains constantly high
over time and shows no sign of decreasing.
Several studies indicate that DKA is associated with a
delay in diagnosis [2, 38] and many children presenting with
DKA have had a medical encounter before diagnosis [2].
Increased disease awareness allows for an earlier diagnosis
of type 1 diabetes, likely preventing the occurrence of DKA,
as suggested by the lower proportion of children diagnosed
with DKA in countries where the incidence of type 1 diabetes
is higher [24, 38, 39]. In addition, screening programmes for
diabetes [11, 40, 41] as well as publicity campaigns [18] have
been considered effective in reducing DKA prevalence at type
1 diabetes diagnosis. However, awareness campaigns targeted
to prevent DKA at type 1 diabetes diagnosis have not shown
uniform results. A reduction in DKA prevalence was reported
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Fig. 3 Annual DKA prevalence (per 100 people) at type 1 diabetes diag-
nosis and estimated annual percentage change (APC) for each country
and all countries combined, during 2006–2016. Solid line, estimated
prevalence trend; dashed line, 95% CI of estimated prevalence trend
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in Italy [18] and Australia [19], whereas no changes were
found in Austria [14] and Wales [30].
Moreover, as recently reviewed [42], all the above-
mentioned studies are limited by methodological issues related
to their observational designs. However, most studies showed
that an awareness campaign targeted to large-scale populations,
and interventions targeted to alert primary healthcare to the
symptoms of type 1 diabetes, are both feasible and acceptable.
Our study did not collect information on local awareness
campaigns but showed an increasing trend in the prevalence of
DKA at diagnosis of type 1 diabetes over the 11 year period,
suggesting that if prevention campaigns had been carried out
locally, the expected effect was not achieved. Effective preven-
tion campaigns should be targeted to reach a high percentage of
the general population and healthcare professionals, should be
repeated and prolonged over time, and shouldmonitor all factors
influencing the occurrence of DKA [15]. Preschool screening
for islet autoantibodies in the general populationmight be useful
to prevent DKA at diagnosis, as shown in a public health screen-
ing programme among children aged 2–5 years in Bavaria,
Germany, in which the prevalence of DKA at diagnosis was
less than 5% [43]. Moreover, screening costs were kept low
by using a relatively inexpensive and sensitive method.
Differences in DKA prevalence between countries The propor-
tion of children with DKA at diagnosis of type 1 diabetes
varies widely between countries. In Europe, the North–South
gradient was confirmed by a higher prevalence of DKA in
countries with low incidence of type 1 diabetes and in those
closer to the equator, compared with countries having a higher
incidence of type 1 diabetes and those that are further from the
equator [22, 44]. In addition, higher proportions of DKA are
more common in countries with a lower HDI. Our data are
consistent with these results, showing an inverse association
between DKA prevalence and HDI and geographical latitude.
Sex differences in DKA prevalence In our analysis, the overall
proportion of girls presenting with DKA was higher than
among boys. Almost all countries showed a slightly higher
proportion of girls presenting with DKA at diabetes diagnosis,
with the exception of Wales where boys more often presented
with DKA at diabetes diagnosis. The reason for the higher
incidence of DKA in the male sex [44] but a higher proportion
of DKA in the female sex is unclear and calls for further
studies. Even if an excess of DKA occurs in girls, as was
recently reported in a large series of children with established
type 1 diabetes [26], a plausible biological, physiological or
clinical explanation is currently very hard to hypothesise.
Perhaps girls are more reluctant to see the associated weight
loss as problematic and, therefore, do not recognise early
symptoms of DKA.
Age differences in DKA prevalence The analysis of this
multicentre large dataset confirms the highest risks of DKA
occur in younger children in all countries except Sweden,
Denmark and New Zealand (Auckland), where the highest
prevalence of DKA were registered in adolescents aged 10–
14.9 years. These findings could be due to less parental aware-
ness of symptoms in very young age groups, or the reluctance
of adolescents to bring their symptoms to parental attention.
Table 3 Time trend for DKA prevalence at type 1 diabetes diagnosis, adjusted for sex, age group and ethnic minority status
Country Year at diabetes
diagnosis
Female vs male sex Age < 5 years
vs 10–14.9 years
Age 5–9.9 years
vs 10–14.9 years
Ethnic minority vs
non-minority status
Australia (ADDN) 1.024 (1.002, 1.046) 1.014 (0.893, 1.152) 1.420 (1.214, 1.660) 0.930 (0.795, 1.089) 1.123 (0.980, 1.286)
Austria 1.000 (0.979, 1.021) 1.105 (0.974, 1.255) 1.157 (0.999, 1.339) 0.789 (0.673, 0.927) 1.361 (1.188, 1.558)
Czechiaa,b 0.995 (0.972, 1.020) 0.993 (0.872, 1.130) 1.227 (1.048, 1.438) 0.911 (0.777, 1.068) –
Denmark 1.021 (0.999, 1.044) 1.179 (1.027, 1.353) 0.911 (0.751, 1.103) 0.809 (0.692, 0.947) 1.533 (1.255, 1.874)
Germany 1.011 (1.003, 1.018) 1.048 (1.000, 1.098) 1.178 (1.112, 1.248) 0.868 (0.822, 0.918) 1.281 (1.208, 1.358)
Italy 0.988 (0.980, 0.995) 1.039 (0.992, 1.088) 1.244 (1.177, 1.315) 0.895 (0.846, 0.947) 1.170 (1.085, 1.262)
Luxembourg 1.000 (0.944, 1.059) 1.312 (0.968, 1.777) 1.743 (1.203, 2.525) 1.152 (0.783, 1.695) 1.075 (0.774, 1.493)
New Zealand (Auckland) 1.021 (0.982, 1.061) 1.187 (0.921, 1.530) 0.827 (0.583, 1.173) 0.683 (0.505, 0.923) 0.881 (0.652, 1.192)
Norway 1.010 (0.990, 1.031) 1.077 (0.949, 1.223) 1.055 (0.898, 1.239) 0.751 (0.646, 0.872) 1.538 (1.262, 1.875)
Sloveniaa,b 1.004 (0.971, 1.037) 1.411 (1.126, 1.768) 1.076 (0.830, 1.396) 0.906 (0.696, 1.179) –
Sweden 1.015 (0.999, 1.031) 1.057 (0.958, 1.166) 0.757 (0.666, 0.86) 0.582 (0.516, 0.655) 1.567 (1.255, 1.958)
USA (SEARCH) 1.063 (1.042, 1.085) 0.954 (0.891, 1.022) 1.234 (1.132, 1.346) 0.986 (0.911, 1.068) 1.141 (1.063, 1.224)
UK (Wales) 0.993 (0.967, 1.020) 0.785 (0.664, 0.929) 1.368 (1.121, 1.670) 0.904 (0.741, 1.105) 1.280 (0.933, 1.756)
All countries combineda 1.007 (1.003, 1.011) 1.038 (1.012, 1.064) 1.176 (1.140, 1.212) 0.863 (0.838, 0.889) –
Data are presented as prevalence ratio (95% CI)
a Adjusted for sex and age group only
b Information on ethnic minority status not given for this country
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Our results, showing a very high prevalence in children under
3 years of age, are consistent with previous observation of
higher DKA risk among the youngest children [21, 25, 39,
45], in whom it may be particularly difficult to recognise signs
and symptoms, leading to delayed diagnosis. Moreover, it has
been reported that in very young children there is more exten-
sive beta cell destruction at diabetes onset [46], which could
be related to a faster and more aggressive disease onset.
Differences in DKA prevalence according to ethnic minority
status In most countries included in our study, an ethnic
minority status was associated with a higher prevalence of
DKA at diabetes diagnosis, as reported in previous worldwide
studies [21, 39]. An ethnic minority status might act as a social
and cultural barrier, negatively affecting the awareness of
disease, the early recognition of symptoms, and the equity in
accessing healthcare services.
Strengths and limitations Strengths of our study include
worldwide collaboration, which allowed the collection of data
from a large number of cases of type 1 diabetes. Moreover,
most of the data used for this study came from population-
based registries or clinical registries with well-defined refer-
ence populations. In addition, data collection was based on
standard inclusion criteria and consistent definitions of DKA
over time. Most countries had data on venous pH and/or
serum bicarbonate levels (11 countries, including 44,617 and
22,426 cases with venous pH and bicarbonate data,
respectively).
Our study has several limitations. Results were based on
retrospective data collection and the study period was relative-
ly short, limiting the precision of trend estimates in each coun-
try. We only included cases of type 1 diabetes with available
information on DKA status, which was the same approach
used in similar studies on DKA at diagnosis of type 1 diabetes
[24]. Consequently, the exclusion of data from individuals
without information on venous pH and/or bicarbonate might
have caused an overestimation of DKA prevalence. However,
in more than 80% of the cases, data for venous pH or bicar-
bonate were available. We suspect that physicians do not
measure venous pH or bicarbonate values if clinical symp-
toms of type 1 diabetes at diagnosis are not severe or, even,
absent, since guidelines concerning children [47] do not clear-
ly indicate that measurement of venous pH and/or bicarbonate
is mandatory at diagnosis of type 1 diabetes. If an individual
had mild symptoms and was not suspected to have DKA (and,
therefore, venous pH was not measured), that person would
have been ‘physician diagnosed’ as not having DKA. Such
evaluation may bias the prevalence estimates, potentially
underestimating the observed burden.
While venous pH and/or bicarbonate provide reliable
data on the proportions of new cases presenting with
DKA, this might not be possible in all settings and
potentially raises cost implications. Serum bicarbonate
can be a reliable substitute for venous pH in settings where
access to venous pH measurement is limited [48]. A basic
metabolic profile (including plasma glucose, venous pH or
bicarbonate, blood urea nitrogen, serum creatinine and
serum electrolytes) and, preferably, a blood ketone
measurement (or, at least, a urine measurement) should
be the standard of care for evaluating new-onset diabetes
mellitus in a child.
Summary In summary, this analysis of 59,000 children
with newly diagnosed type 1 diabetes, from different
countries, showed a high prevalence of children present-
ing with DKA at diabetes diagnosis with large inter-
country differences and a slight increase in prevalence
over time. Despite the present lack of effective measures
to reduce the risk of DKA at diabetes diagnosis, our find-
ings of high prevalence of DKA at diagnosis of diabetes
must be considered worrying for all countries and espe-
cially for those with access to advanced healthcare
systems. These findings should be considered as a call
for action to put more effort into promoting an earlier
diagnosis of diabetes to prevent DKA in children and
adolescents worldwide. Collaborative approaches such
as this help gain a better understanding of the prevalence
of DKA at diagnosis of diabetes, to inform development
of interventions to improve patient outcomes.
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